Author Archives: Bruno Quinney

#Biomarkers #Genetics #GLP-1 #Weight loss

Genetic markers could predict GLP-1 efficacy, data shows 

Genetic biomarkers could predict GLP-1 efficacy response, results show.  Human omics company Ovation.io and precision medicine company PrecisionLife have released findings from the first phase of their collaboration, showing biomarkers can predict the efficacy, safety and tolerability of GLP-1 therapies.  Using Ovation’s longitudinal clinical and… Read More

#News

#Clinical trial #Liverpool School of Tropical Medicine

Ophirex to produce snake venom inhibitor for LSTM study 

Public benefit corporation Ophirex has entered an agreement to produce a snake venom inhibitor for the Liverpool School of Tropical Medicine (LSTM).  Marimastat is an inhibitor of snake venom metalloproteinases, a major snake venom toxin which plays a primary role in the digestion of tissues, leading to swelling, necrosis and internal… Read More

#News

Woman standing on scales
#Biopharmaceutical #Clinical trial #GLP-1 #Weight loss

Verdiva Bio completes enrolment for oral GLP-1 trial 

Biopharmaceutical company Verdiva Bio has completed its participant enrolment for the Phase IIb study of its once-weekly oral GLP-1.  VRB-101 is a once-weekly oral, cAMP-biased, GLP-1 peptide analogue candidate for body weight reduction in people with overweight or obesity.  The Phase IIb EVOLVE-2 trial is randomised, double-blind… Read More

#News

Bacteria in Petri dishes
#Antimicrobial resistance (AMR) #Centauri Therapeutics #Gram-negative bacteria

Centauri raises financing with AMR Action Fund investment 

Immunotherapy company Centauri Therapeutics has extended its Series A financing to £30 million ($40.6 million) to support its lead candidate targeting Gram-negative bacterial infections.  The funding was extended thanks to a £6m ($8.1 million) investment from the AMR Action Fund. The financing from AMR Action Fund, the world’s… Read More

#Business & Investment #News

Hydrogel
#Phase II trial #SolasCure

Gel could heal chronic wounds seven times faster, data shows 

A new gel could heal chronic wounds seven times faster than current standard of care, data suggests.  Biotechnology company SolasCure has released data from its Phase II trial of the Aurase Wound Gel (AWG), showing the gel demonstrated 22 times faster debridement and seven times faster healing compared to standard of care.  … Read More

#News

Non-Hodgkins lymphoma
#Bispecific Antibodies #Follicular lymphoma #National Institute for Health and Care Excellence (NICE)

NICE recommends first bispecific antibody to treat lymphoma 

The National Institute for Health and Care Excellence (NICE) has recommended the first bispecific antibody for the treatment of follicular lymphoma (FL).  Tepkinly (epcoritamab), developed by biopharmaceutical company AbbVie, has been recommended to the NHS as an option to treat adult patients with FL whose cancer has returned… Read More

#News #Regulatory

Female scientists conducting research on samples
#Nuclear medicine #Prostate cancer

EANM launches award for prostate cancer research 

The European Association of Nuclear Medicine (EANM) has launched an award for research in prostate cancer treatment.  The 2026 EANM Young Scientist Network Award, aiming to accelerate innovation in alpha radioligand therapy in prostate cancer, offers three prizes of €40,000 (Platinum), €20,000 (Gold) and €10,000 (Silver). … Read More

#Cancer Research #News

MRI of the brain
#Brain #epilepsy #Novel therapeutics

Angelini and Quiver to collaborate on epilepsy therapeutics 

Brain health company Angelini Pharma has announced a strategic collaboration with biotechnology company Quiver Bioscience to discover and advance novel therapeutics to genetic epilepsies.  The collaboration, which also includes a licensing agreement, brings together Quiver’s drug discovery capabilities, data assets and AI models with Angelini Pharma’s expertise in brain health and… Read More

#News

Stem cell transplant
#Biologics License Application (BLA) #Clinical trial #FDA

FDA accepts BLA for kidney transplant drug imlifidase

The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for a drug desensitising highly sensitised adult kidney transplant patients.  Imlifidase, developed by biopharmaceutical company Hansa Pharma, is a unique IgG cleaving enzyme that rapidly inactivates over 95% of donor–specific antibodies within two to… Read More

#News #Regulatory

Ovarian cancer cells
#Cancer research #European Innovation Council #Ovarian cancer #Women's health

EIC awards €2.5m grant for gynaecological cancer drug 

The European Innovation Council (EIC) has awarded €2.5 million to biotechnology company Step Pharma to accelerate the development of dencatistat for CTPS2 null gynaecological tumours.  The funding, which consists of a €2.5 million grant and potentially up to €10 million in equity investment, is part of the EIC’s Accelerator Award,… Read More

#Cancer Research #News #Regulatory

Medical laboratory
#ABPI #Clinical trial #UK

Boost in trial activity would have huge gains, report says 

A new report has highlighted the health and economic opportunity from boosting industry clinical trials.  A report from the European Federation of Pharmaceutical Industries and Associations (EFPIA) highlights increasing clinical trial activity across Europe would have significant health, economic and productivity returns.  According to… Read More

#News

#HIV #The New England Journal of Medicine #ViiV Healthcare

Injectable HIV drug more effective than daily oral therapy 

An injectable treatment for HIV could be more effective than a daily oral therapy, data suggests.  Results from the LATITUDE study of Cabenuva (cabotegravir + rilpivirine), a long-acting injectable developed by HIV specialist ViiV Healthcare, show the switch to the injectable reduced risk of virological failure by nearly half compared to… Read More

#News